-

05:21:51 PM

CNTB Stock News

CNTB - Connect Biopharma Holdings Ltd

03/18/23 2:40 PM

Nasdaq : CNTB

low float

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the...

RHEA-AI

neutral

03/17/23 4:05 PM

Nasdaq : CNTB

clinical triallow float

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that post hoc data analysis from the Phase 2 b CBP-201 global trial in moderate-to-severe atopic dermatitis showed that CBP-201 led to rapid and...

RHEA-AI

positive

03/06/23 8:15 AM

Nasdaq : CNTB

low float

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that two abstracts from its CBP-201 clinical development program in atopic dermatitis have been accepted for presentation at the American Academy...

RHEA-AI

very positive

02/06/23 8:30 AM

Nasdaq : CNTB

conferenceslow float

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting, and hosting

RHEA-AI

neutral

12/30/22 7:30 AM

Nasdaq : CNTB

clinical triallow float

Connect Biopharma Provides Business and Clinical Development Program Update

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program Progress of China

RHEA-AI

very positive

12/19/22 8:00 AM

Nasdaq : CNTB

conferenceslow float

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that

RHEA-AI

neutral

12/02/22 5:00 PM

Nasdaq : CNTB

low float

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that,

RHEA-AI

neutral

10/27/22 4:05 PM

Nasdaq : CNTB

conferenceslow float

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting and/or hosting

RHEA-AI

neutral

10/04/22 8:56 AM

Nasdaq : CNTB

low float

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

In a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note that in the "About the Trial" section, the fourth sentence should read "Stage 2 36-week maintenance period",

RHEA-AI

neutral

10/04/22 7:00 AM

Nasdaq : CNTB

low float

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD Safety and tolerability results for CBP-201 consistent with targeting the IL-4Rα pathway Data support advancing the regulatory discussions with the CDE for submitting

RHEA-AI

neutral

CNTB Data

IndustryResearch and Development in Biotechnology
Websitewww.connectbiopharm.com
Security nameConnect Biopharma Holdings Ltd - ADR
Issue typead
SectorProfessional, Scientific, and Technical Services
Sic code2834
Employees108

About Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).